

UDK 616.12-005.3:616.125-008.313.2]-036.12

ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE

¹Igamberdiyeva R.Sh., ¹Abdullayev Sh.S., ²Yerina M.U.

¹Tashkent pediatric medical institute,
100125 Uzbekistan Tashkent, Bogishamol 223
²St. Petersburg state pediatric medical university,
194100 Russian Federation, St. Petersburg, st. Litovskaya 2

Resume

In patients with chronic kidney disease (CKD) develop bleeding and thrombotic tendencies, so the indication of anticoagulation therapy at the onset of atrial fibrillation (AF) is complex. AF is the most common chronic cardiac arrhythmia, and thromboembolism and ischemic stroke in particular are major complications.

Key words: *chronic kidney disease, atrial fibrillation, new oral anticoagulants.*

ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ И ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК

¹Игамбердиева Р.Ш., ¹Абдуллаев Ш.С., ²Ерина М.Ю.

¹Ташкентский педиатрический медицинский институт,
100125 Узбекистан, Ташкент, Богишамол 223
²Санкт-Петербургский государственный педиатрический медицинский университет,
194100 Российская Федерация, Санкт-Петербург, улица Литовская 2

Резюме

У пациентов с хроническим заболеванием почек (ХБП) развиваются склонности к кровотечениям и тромбоемболиям, поэтому показание к применению антикоагулянтов при присоединении фибрилляции предсердий (ФП) является сложным. ФП является наиболее распространенной хронической сердечной аритмией, а тромбоемболия и ишемический инсульт, в частности, являются основными осложнениями.

Ключевые слова: *хроническая болезнь почек, фибрилляция предсердий, новые оральные антикоагулянты.*

БЎЛМАЧАЛАР ФИБРИЛЛЯЦИЯСИ ВА СУРУНКАЛИ БУЙРАК КАСАЛЛИГИ

¹Игамбердиева Р.Ш., ¹Абдуллаев Ш.С., ²Ерина М.Ю.

¹Тошкент педиатрия тиббиёт институти, 100125 Ўзбекистон Тошкент, Богишамол 223
²Санкт-Петербург давлат педиатрия тиббиёт университети,
194100 Россия Федерацияси, Санкт-Петербург, Литовскаякўчаси 2

Резюме

Сурункали буйрак касаллиги (СБК) бўлган беморларда қон кетишига ҳамда тромбоемболияларга мойиллик хавфи кескин ортади, шунинг учун ҳам бўлмачалар фибрилляцияси (БФ) қўшилганда антикоагулянтларни қўллашига жуда эҳтиёткорлик билан ёндашишни талаб этади. БФ кенг тарқалган сурункали аритмиялардан бири ҳисобланади ва у кўпинча тромбоемболия ҳамда ишемик инсультлар билан асоратланади.

Калит сўзлар: сурункали буйрак касаллиги, бўлмачалар фибрилляцияси, янги орал антикоагулянтлар.

Introduction

Atrial fibrillation (AF) is the most common arrhythmia in patients with chronic kidney disease (CKD) [1]. Moreover, in patients with CKD, AF is associated with a greater the frequency of both ischemic stroke (systemic embolism) and bleeding compared with the general population of patients with AF.

Continuous administration of oral anticoagulants is the most effective form of prevention of thrombotic complications in patients with AF. In European recommendations for the diagnosis and treatment of AF 2016 after studying the results carried out at that time direct oral anticoagulant studies (PAA) were deemed preferable to the appointment (in the absence of contraindications) than warfarin, in patients with AF and retained, as well as moderately reduced (CC 30–49 ml/min) filtration function kidneys [2].

Use of NOAC in patients with AF and concomitant CKD requires the selection of the correct doses of drugs in connection with various renal clearance of representatives NOAC class and the need to maintain balance "Benefit / risk". However, in the literature there are practically no data on prospective studies of NOAC, as well as comparing them with AF combined with CKD. Published several sub-analyzes of the main randomized clinical trials (RCTs) -RE-LY, ROCKET AF, ARISTOTLE in patients with AF, depending on the degree of decrease in filtration function kidneys [3-6]. The disadvantages of this type of data collection can be attributed a retrospective nature, as well as a comparison of each NOAC (rivaroxaban) with warfarin only. Also in a number work and clinical observations are data on that NOAC, like warfarin, can lead to the development of anticoagulant-associated nephropathy [7]. In currently, to understand the

efficacy and safety of using NOAC in a cohort of patients with CKD There are several studies conducted among patients with end-stage CKD, as well as studies assessing the impact of NOAC on the progression of CKD (study XARENO, NCT02663076 [8]; RE-ELECT, NCT03789695 [9]).

The aim of our work was to evaluate the effect of oral anticoagulants (warfarin and rivaroxaban) on the filtration function kidney in everyday clinical practice in patients with AF, depending on the stage of CKD, and compare the effectiveness and safety of drugs with each other.

Materials and methods

We conducted a prospective single-center non-randomized non-interventional observational study in parallel groups evaluating the effectiveness and safety of use warfarin and available in Uzbekistan NOAK (rivaroxaban) in patients with moderately reduced renal function, as well as their effect on the filtration capacity of the kidneys (median follow-up was 10 months). A total of 127 patients were included in the study with AF: 92 with diagnosed CKD (CKD group (+)) and 35 without CKD (CKD group (-)). Average age of participant's patients amounted to 72.2 ± 8.5 years. Patients had high risk of thrombotic complications (average 4 points on a scale CHA₂DS₂-VASc) and a moderate risk of developing major bleeding (HAS-BLED average score of 1.4). Of concomitant pathology most often (in 96.1%) there was arterial hypertension (AH), a quarter of patients (25.2%) suffered from type 2 diabetes mellitus. Row patients had a history of cardiovascular events (17.3% of patients had previously myocardial infarction (MI), and 18.9% - ischemic stroke or transient ischemic attack (TIA)). Comparative characteristics of patients from groups CKD (+) and CKD (-) are presented in table 1.

Table 1. Comparative characterization of patients with AF depending on the concomitant presence of CKD


Patient characteristics	CKD(+) n-92	CKD(-) n-35	P
Men	36 (39,1%)	18 (51,4%)	0,21
Women	56 (60,9%)	17 (48,6%)	0,21
Average age, years	73,8±7,82	68,0±8,89	<0,001
Average BMI, kg/m ²	29,5±5,28	28,3±4,14	0,26
HAS-BLED average, score	1,6±0,83	1,1±0,83	<0,01
CHA ₂ DS ₂ -VASc average, score	4,3±1,47	3,1±1,48	<0,001
GFR (CKD-EPI) media, ml/min/1,73m ²	54,1±16,13	79,3±10,59	<0,001
CC (by Cocroft-Gault) med,ml/min	62,7±23,53	89,4±23,55	<0,001
Concomitant pathology			
Stroke/TIA	19 (20,7%)	5 (14,3%)	0,57
Previous MI	17 (18,5%)	5 (14,3%)	0,77
Diabetes	27 (29,3%)	5 (14,3%)	0,13
Arterial hypertension	90 (97,8%)	32 (91,4%)	0,13
CHF (FV≤40%)	9 (9,8%)	5 (8,6%)	1,00

Significant differences between the groups were obtained by age (in the CKD group (+) patients were significantly older than patients from the CKD group (-), p <0.001), the number of points on the scales CHA₂DS₂-VASc and HAS-BLED (in the CKD (+) group, patients had a greater risk as thrombotic and hemorrhagic events), as well as in terms of renal filtration function (GFR according to CKD-EPI and CC), which is consistent with the

characteristics of patients with CKD in the population.

All patients under observation every 3 months assessed the dynamics of filtration kidney function as well as efficacy and safety anticoagulant therapy. Depending on the anticoagulant taken, patients in the CKD (+) group were divided as follows (Fig. 1).

Figure 1. Disposition of patients with AF and CKD to drugs and drug dosages



Most often, patients with CKD in our sample from the CKD group (+) took rivoraxaban, second in frequency of appointments (27%). Distribution of CKD Patients in a Study by the stages are presented in table 2.

Table 2. Disposition of patients with AF and CKD stages

CKD stages	GFR (CKD-EPI)	Number of patients
C1	>90 ml/min/1,73m ²	5 (54%)
C2	60-89 ml/min/1,73m ²	28 (30,4%)
C3a	45-59 ml/min/1,73m ²	31 (33,7%)
C3b	30-44 ml/min/1,73m ²	26 (28,3%)
C4	15-29 ml/min/1,73m ²	2 (2,2%)

In our work, patients with 3a-, 2- and 3b-stages of CKD (in total - 92.4% of the total numbers with AF and CKD).The initial characteristics of the

filtration function kidneys (CC, GFR) in patients with CKD taking various NOAK and warfarin did not differ significantly.

Table 3.Comparative characterization of patients with AF and CKD depending on anticoagulant taken

Indicator	Rivaroxaban (67)	Warfarin (25)	P
Average age, years	75,7±6,61	74,4±7,82	0,155
HAS-BLED, points±SD	1,5±0,79	1,8±0,72	0,240
CHA ₂ DS ₂ -VASc, points±SD	4,3±1,49	4,2±1,46	0,143
GFR (CKD-EPI) med, ml/min/1.73m ²	56,8±18,02	51,0±17,11	0,412
CC (by Cocroft-Gault) med, ml/min	60,4±24,91	56,3±19,13	0,113

In general, patients taking different AC did not differ. However, in a pair wise comparison, patients taking warfarin were significantly younger than patients taking rivaroxaban (p = 0.047). And in the group warfarin turned out to be patients with a significantly higher estimated risk of bleeding on the HAS-BLED scale, than patients in the rivaroxaban group (p = 0.036).

The initial characteristics of the filtration function kidney (creatinine clearance and GFR) in patients with AF and CKD, depending on the drug they receive, did not differ significantly. However, a pair wise comparison showed a significant

difference in QC between groups of patients taking warfarin and rivaroxaban: in the group receiving rivaroxaban, QC was significantly lower (p = 0.01).

RESULTS

During the observation period, we did not reveal any significant changes in the filtration function of the kidneys in anyone of the groups (Fig. 2–4).

Figure 2.Dinamics of creatinin level (mcmol/l) in patients with CKD on various oral anticoagulants




Figure 3.Dinamics of GFR (CKD-EPI, ml/min/1.73m²) in patients with CKD on various oral anticoagulants






Figure 4. Dynamics of CC (ml/min) in patients with CKD on various oral anticoagulants



Despite the high estimated risk of thrombotic events on the scale CHA₂DS₂-VASc (4.3 ± 1.47 points) in group of patients with CKD, we did not observe any thromboembolic complications of AF in any of the drugs, which can be explained by a not so long period observations. Quite significant, on the other hand the clinical fact is that for all the time of our there were no large cases of observation with warfarin and NOAC in patients with AF and

CKD bleeding. We recorded 25 small hemorrhagic events that did not require cancellation anticoagulant therapy (with the exception of one minor clinically significant bleeding from a stomach ulcer, in which temporary withdrawal was performed anticoagulant with subsequent resumption of its intake). The distribution of hemorrhagic events, depending on the drug taken and its dosage, is presented in Figure 5.

Figure 5. Bleeding rate depending on the anticoagulant and its dose in patients with AF and CKD (%)



Discussion

In a subanalysis of the study ROCKET-AF Christopher B. Fordyce Coll. also revealed greater reduction in CC in patients receiving warfarin (-4.3 ± 14.6 ml/min) compared with patients receiving rivaroxaban (-3.5 ± 15.1 ml / min, $p < 0.001$) [11]. The above work allowed suggest a nephroprotective effect in class NOAC, however, the reliability of these data is limited by the retrospectiveness of their receipt. The main limitations of our study are the lack of randomization, open character research, a short observation period and limited number of patients involved. There are the data obtained on the differences between groups of drugs should be interpreted with caution. In any case, the role of small bleeding due to the fact that they often become the cause of interruption / cessation of anticoagulant therapy, and this, in turn, significantly increases the risks of thromboembolic complications of AF, and also an unfavorable

predictor of overall mortality in patients with AF [12].

Conclusions

In general, we can conclude that the reception of other NOAC or warfarin by patients with AF and CKD did not significantly affect the dynamics of renal filtration function, which may be related to the concomitant nephroprotective therapy obtained in a large percentage of cases. Pooh probably have a nephroprotective effect only relatively Comparison with Vitamin K Antagonist Therapy various NOAK (as well as warfarin) in patients with AF and CKD for a little less than a year was not accompanied by the development of thromboembolic complications and large bleeding, which is in favor of its effectiveness and safety. In connection with a significantly large the number of hemorrhagic events in the background with warfarin, regardless of its dose, in patients with AF and moderate CKD, treatment with rivaroxaban can be considered preferred.

LITERATURE:

- Olesen J.B. et al, Stroke and bleeding in atrial fibrillation with chronic kidney disease. *N Engl J Med.* 2012;367(7):625-35.
- Kirchhof P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organization (ESO). *Eur Heart J.* 2016.
- Hijazi Z. et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. *Circulation.* 2014;129(9):961-70.
- Fox K.A. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *European Heart J.* 2011;32(19):2387-94.
- Racchah B.H. et al. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: Systematic Review and Meta-Analysis of Randomized Trials. *Chest.* 2016;149(6):1516-24.
- Wheeler D.S., Giugliano R.P. and Rangaswami J. Anticoagulation-related
- Factor XA – Inhibition in RENal patients with Non-valvular Atrial fibrillation - Observational Registry (XARENO). Cited 2019 18/02.
- Rivaroxabanvs Warfarin in AF patients with T2D and CKD (RE-ELECT). Cited 2019 18/02.
- Bohm M. et al. Changes in renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. *J AM CollCardiol* 2015;65(23):2481-93.
- Hijazi Z. et al. Efficacy and safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. *JAMA Cardiol.* 2016;1(14):451-60.
- Fumagally S., Said S.A.M., Laroche C., Gabbai D., Marchionni N, Boriani G., Maggioni A.P., Popescu M.I., Rasmussen R.H. et al. Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). *J Am CollCardiol EP.* 2015; 1:326-34.
- Abdullaev Sh.S., Igamberdieva R.Sh. The use of new oral anticoagulants for atrial fibrillation in patients with chronic kidney disease. *Therapeutic Bulletin of Uzbekistan* 2018; 4: 151-155.

Entered 02.01. 2020